🇺🇸 FDA
Patent

US 11419942

Angiotensinogen (AGT) iRNA compositions and methods of use thereof

granted A61KA61K45/06A61K47/549

Quick answer

US patent 11419942 (Angiotensinogen (AGT) iRNA compositions and methods of use thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
55
CPC classes
A61K, A61K45/06, A61K47/549, A61P, A61P11/00